Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary
- PMID: 22674743
- DOI: 10.1002/j.1875-9114.2012.01143_1.x
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary
Comment on
-
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.Pharmacotherapy. 2012 Apr;32(4):323-32. doi: 10.1002/j.1875-9114.2012.01048. Pharmacotherapy. 2012. PMID: 22461122 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
